Review
Medicine, Research & Experimental
Calvin D. De Louche, Ali Roghanian
Summary: In recent decades, immunotherapeutic strategies have been used to treat a wide range of previously incurable pathologies, but a considerable number of patients do not respond or develop resistance to current immunotherapies. Therefore, developing the next generation of immune-targeted therapies is urgently needed. Human LILRBs play important roles in regulating immune functions, and blocking these inhibitory receptors can enhance immune responses.
Article
Multidisciplinary Sciences
Yan Zhu, Wenjie Sun, Xueping Jiang, Rui Bai, Yuan Luo, Yanping Gao, Shuying Li, Zhengrong Huang, Yan Gong, Conghua Xie
Summary: Different transcript variants of WRAP53 gene have different functions in non-small cell lung cancer cells and regulate cell behaviors depending on the expression level of p53.
Article
Cell Biology
Danielle S. Potter, Ruochen Du, Patrick Bhola, Raphael Bueno, Anthony Letai
Summary: By utilizing dynamic BH3 profiling (DBP) to measure drug-induced mitochondrial apoptotic priming, it is possible to identify drugs that render tumors more sensitive to conventional chemotherapy and to rationally construct combination therapies. Research has shown that targeted agents that increase priming of NSCLC tumor cells can enhance sensitivity to chemotherapy both in vitro and in vivo.
CELL DEATH & DISEASE
(2021)
Article
Cell Biology
Zhe Liu, Liang Ma, Yiming Sun, Wenying Yu, Xue Wang
Summary: The study demonstrated that the STAT3/ZEB1 axis is critical in gefitinib resistance in lung cancer, and a new potential therapeutic strategy targeting STAT3 has been identified with the inhibitor LL1. LL1 was shown to sensitize resistant cells to gefitinib by depleting STAT3 activity and blocking its signaling pathways, with little observed toxicity in animal models, indicating it could be a chemotherapeutic adjuvant for gefitinib resistance in NSCLC.
CELL DEATH & DISEASE
(2021)
Article
Cell Biology
Fraser R. Millar, Adam Pennycuick, Morwenna Muir, Andrea Quintanilla, Priya Hari, Elisabeth Freyer, Philippe Gautier, Alison Meynert, Graeme Grimes, Carla Salomo Coll, Sofia Zdral, Stella Victorelli, Vitor H. Teixeira, John Connelly, Joao F. Passos, Marian A. Ros, William A. H. Wallace, Margaret C. Frame, Andrew H. Sims, Luke Boulter, Sam M. Janes, Simon Wilkinson, Juan Carlos Acosta
Summary: Targeting Toll-like receptor 2 (TLR2), a key regulator of oncogene-induced senescence, can impede early lung cancer progression by activating cell intrinsic cell cycle arrest pathways and the proinflammatory SASP. This discovery suggests TLR2 as a potential therapeutic target for lung cancer.
Article
Biology
Xiaolong Tang, Lizhi Cheng, Guo Li, Yong-Ming Yan, Fengting Su, Dan-Ling Huang, Shuping Zhang, Zuojun Liu, Minxian Qian, Ji Li, Yong-Xian Cheng, Baohua Liu
Summary: The small molecule compound D6 demonstrates promising efficacy in treating EGFR-TKI resistant NSCLC by targeting the protein-protein interaction between HSP90 and T790M-EGFR, offering a potential alternative strategy to overcome drug resistance.
COMMUNICATIONS BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Joanna Moes-Sosnowska, Monika Skupinska, Urszula Lechowicz, Ewa Szczepulska-Wojcik, Paulina Skronska, Adriana Rozy, Aneta Stepniewska, Renata Langfort, Piotr Rudzinski, Tadeusz Orlowski, Delfina Popiel, Aleksandra Stanczak, Maciej Wieczorek, Joanna Chorostowska-Wynimko
Summary: This study comprehensively evaluated the expression, fusions, and variants of FGFR in Sq-NSCLC. The findings provide insights into the molecular background of Sq-NSCLC and suggest that combining different methods can improve the detection rate of FGFR aberrations, which may have implications for treatment selection.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Humna Hasan, Ikjot Singh Sohal, Zulaida Soto-Vargas, Anjali M. Byappanhalli, Sean E. Humphrey, Hana Kubo, Sarunya Kitdumrongthum, Sarah Copeland, Feng Tian, Arthit Chairoungdua, Andrea L. Kasinski
Summary: Extracellular vesicles (EVs) released from non-small cell lung cancer (NSCLC) cells play a crucial role in promoting cancer progression. There are differences in the secretion profile and the ability to induce phenotypic changes in non-tumorigenic cells among EVs derived from different NSCLC cell lines. EV-encapsulated RNA (EV-RNA) is identified as a key factor in mediating these phenotypes. The aggressiveness of NSCLC subtypes may be correlated with the ability of their respective EVs to induce cancerous phenotypes.
SCIENTIFIC REPORTS
(2022)
Article
Multidisciplinary Sciences
Chuantao Zhang, Man Jiang, Na Zhou, Helei Hou, Tianjun Li, Hongsheng Yu, Yuan-De Tan, Xiaochun Zhang
Summary: Using gene differential expression and gene ontology, a set of 26 tumor suppressor genes were identified, with SASH1, STARD13, CBFA2T3, and RECK showing strong tumor suppressor effects, and EXT1, PTCH1, KLK10, and APC demonstrating weak tumor suppressor effects. These genes can be used as specific and sensitive biomarkers for diagnosis of NSCLC cancer.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Yoko Miura, Shyuntaro Isogai, Shinji Maeda, Satoshi Kanazawa
Summary: CD80 interacts with CD28 and CTLA-4 on antigen-presenting cells to regulate T cell activity. CTLA-4-Ig is used to treat rheumatoid arthritis by blocking co-stimulatory signaling. The study shows that CTLA-4-Ig treatment improves chronic inflammatory polyarthritis and has an effect on the inflamed synovial compartment through the CD80 and PD-L1 axes.
SCIENTIFIC REPORTS
(2022)
Article
Multidisciplinary Sciences
Hongxia Li, Emily B. Harrison, Huizhong Li, Koichi Hirabayashi, Jing Chen, Qi-Xiang Li, Jared Gunn, Jared Weiss, Barbara Savoldo, Joel S. Parker, Chad Pecot, Gianpietro Dotti, Hongwei Du
Summary: Therapeutic options for non-small cell lung cancer patients with brain metastases are limited. CAR-T cells targeting B7-H3 and expressing the chemokine receptor CCR2b show improved accumulation in the brain and enhanced anti-tumor activity. This strategy could improve the efficacy of adoptive T-cell therapies in patients with solid tumors presenting with brain metastases.
NATURE COMMUNICATIONS
(2022)
Article
Health Care Sciences & Services
Eva Obermayr, Nina Koppensteiner, Nicole Heinzl, Eva Schuster, Barbara Holzer, Hannah Fabikan, Christoph Weinlinger, Oliver Illini, Maximilian Hochmair, Robert Zeillinger
Summary: This study highlighted the importance of molecular characterization of circulating tumor cells (CTCs) in NSCLC patients. The analysis found that cancer stem cell-related transcripts were significantly associated with overall survival at both primary diagnosis and disease progression.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Federica Liotti, Maria Marotta, Daniela Sorriento, Emanuela Pone, Francesco Morra, Rosa Marina Melillo, Nella Prevete
Summary: TLR7, PRR, and FPR1 have been identified as potential regulators in inhibiting angiogenesis and inflammation resolution in cancer. The study suggests new strategies for the treatment of lung and gastric cancer.MAPK and STAT3 signaling play a crucial role in these activities.
Article
Cell Biology
Xiao-Wei Zhang, Lin Li, Wen-Qian Hu, Ming-Ning Hu, Yan Tao, Hui Hu, Xiao-Kang Miao, Wen-Le Yang, Qiong Zhu, Ling-Yun Mou
Summary: This study reveals that G protein-coupled receptor neurokinin-1 (NK1R) is significantly upregulated in lung cancer samples and is associated with advanced clinical stages and poor prognosis. NK1R co-expresses with epidermal growth factor receptor (EGFR) and interacts with it in tumor cells. Activation of NK1R promotes lung cancer cell proliferation and migration through EGFR signaling pathways. Inhibition of NK1R suppresses cell proliferation and migration, and knockdown of NK1R slows down tumor growth. The presence of a selective NK1R antagonist enhances the sensitivity of lung cancer cells to specific drugs.
CELL DEATH & DISEASE
(2022)
Article
Multidisciplinary Sciences
Nathan Farrokhian, Jeff Maltas, Mina Dinh, Arda Durmaz, Patrick Ellsworth, Masahiro Hitomi, Erin McClure, Andriy Marusyk, Artem Kaznatcheev, Jacob G. Scott
Summary: In this study, the frequency-dependent interactions between a gefitinib-resistant non-small cell lung cancer population and its sensitive ancestor were measured experimentally. The cost of resistance was found to be insufficient in predicting competitive exclusion, and frequency-dependent growth rate measurements were necessary. Simulations showed that ecological growth effects can influence the predicted extinction time.